Medtronic Presents Positive Data from Symplicity HTN-1
September 03, 2013 at 05:59 AM EDT
Medtronic, Inc. (NYSE: MDT ), announced today at the European Society of Cardiology (ESC) Congress the final three-year results from Symplicity HTN-1, the first and longest running clinical study investigating the safety and efficacy of renal denervation, which also have been accepted for publication in The Lancet. Eighty-eight (88)
